Matthew W Sherwood1,2, Todd L Kiefer3. 1. Inova Heart and Vascular Institute, 3300 Gallows Rd. 1st floor Suite 1225, Falls Church, VA, 22042, USA. matthew.sherwood@inova.org. 2. Duke Clinical Research Institute, 2400 Pratt Street, P.O. Box 17969, Durham, NC, 27715, USA. matthew.sherwood@inova.org. 3. Division of Cardiology, Duke University Medical Center, 2301 Erwin Road, Durham, NC, 27710, USA.
Abstract
PURPOSE OF REVIEW: We will describe and define the current diagnosis, management, and potential therapy for low-flow aortic stenosis (AS) states, as well as summarize the available evidence underlying these recommendations. RECENT FINDINGS: Low-flow aortic stenosis syndromes have worse prognoses than traditionally defined normal flow severe aortic stenosis. In this setting, aortic valve replacement is the only therapy that improves outcomes. Transcatheter aortic valve replacement has an ever-expanding role in the treatment of aortic stenosis, and there is growing evidence that TAVR may be a preferred therapy for low-flow AS states. Aortic stenosis remains one of the most common valvular diseases requiring therapy. Low-flow AS represents up to 40% of all patients with AS and is associated with significant mortality. This condition requires further testing for appropriate diagnosis and treatment. Low-flow AS states have poor prognoses, thus AVR and especially TAVR have a growing role in treatment of this challenging subset of AS patients.
PURPOSE OF REVIEW: We will describe and define the current diagnosis, management, and potential therapy for low-flow aortic stenosis (AS) states, as well as summarize the available evidence underlying these recommendations. RECENT FINDINGS: Low-flow aortic stenosis syndromes have worse prognoses than traditionally defined normal flow severe aortic stenosis. In this setting, aortic valve replacement is the only therapy that improves outcomes. Transcatheter aortic valve replacement has an ever-expanding role in the treatment of aortic stenosis, and there is growing evidence that TAVR may be a preferred therapy for low-flow AS states. Aortic stenosis remains one of the most common valvular diseases requiring therapy. Low-flow AS represents up to 40% of all patients with AS and is associated with significant mortality. This condition requires further testing for appropriate diagnosis and treatment. Low-flow AS states have poor prognoses, thus AVR and especially TAVR have a growing role in treatment of this challenging subset of AS patients.
Authors: J K Oh; C P Taliercio; D R Holmes; G S Reeder; K R Bailey; J B Seward; A J Tajik Journal: J Am Coll Cardiol Date: 1988-06 Impact factor: 24.094
Authors: Björn Redfors; Philippe Pibarot; Linda D Gillam; Daniel Burkhoff; Jeroen J Bax; Brian R Lindman; Robert O Bonow; Patrick T O'Gara; Martin B Leon; Philippe Généreux Journal: Circulation Date: 2017-05-16 Impact factor: 29.690
Authors: Samir R Kapadia; Martin B Leon; Raj R Makkar; E Murat Tuzcu; Lars G Svensson; Susheel Kodali; John G Webb; Michael J Mack; Pamela S Douglas; Vinod H Thourani; Vasilis C Babaliaros; Howard C Herrmann; Wilson Y Szeto; Augusto D Pichard; Mathew R Williams; Gregory P Fontana; D Craig Miller; William N Anderson; Jodi J Akin; Michael J Davidson; Craig R Smith Journal: Lancet Date: 2015-03-15 Impact factor: 79.321
Authors: Helmut Baumgartner; Judy Hung; Javier Bermejo; John B Chambers; Thor Edvardsen; Steven Goldstein; Patrizio Lancellotti; Melissa LeFevre; Fletcher Miller; Catherine M Otto Journal: J Am Soc Echocardiogr Date: 2017-04 Impact factor: 5.251
Authors: Marie-Annick Clavel; Maxime Berthelot-Richer; Florent Le Ven; Romain Capoulade; Abdellaziz Dahou; Jean G Dumesnil; Patrick Mathieu; Philippe Pibarot Journal: J Am Coll Cardiol Date: 2015-02-24 Impact factor: 24.094
Authors: Rick A Nishimura; J Aaron Grantham; Heidi M Connolly; Hartzell V Schaff; Stuart T Higano; David R Holmes Journal: Circulation Date: 2002-08-13 Impact factor: 29.690
Authors: Sammy Elmariah; Igor F Palacios; Thomas McAndrew; Irene Hueter; Ignacio Inglessis; Joshua N Baker; Susheel Kodali; Martin B Leon; Lars Svensson; Philippe Pibarot; Pamela S Douglas; William F Fearon; Ajay J Kirtane; Hersh S Maniar; Jonathan J Passeri Journal: Circ Cardiovasc Interv Date: 2013-11-12 Impact factor: 6.546
Authors: Marc R Dweck; Sanjiv Joshi; Timothy Murigu; Francisco Alpendurada; Andrew Jabbour; Giovanni Melina; Winston Banya; Ankur Gulati; Isabelle Roussin; Sadaf Raza; Nishant A Prasad; Rick Wage; Cesare Quarto; Emiliano Angeloni; Simone Refice; Mary Sheppard; Stuart A Cook; Philip J Kilner; Dudley J Pennell; David E Newby; Raad H Mohiaddin; John Pepper; Sanjay K Prasad Journal: J Am Coll Cardiol Date: 2011-09-13 Impact factor: 24.094
Authors: Kumar Dharmarajan; Jill Foster; Megan Coylewright; Philip Green; John P Vavalle; Osman Faheem; Pei-Hsiu Huang; Amar Krishnaswamy; Vinod H Thourani; Lisa A McCoy; Tracy Y Wang Journal: PLoS One Date: 2017-04-21 Impact factor: 3.240
Authors: Cynthia Al Hageh; Ryan Rahy; Georges Khazen; Francois Brial; Rony S Khnayzer; Dominique Gauguier; Pierre A Zalloua Journal: PLoS One Date: 2020-11-25 Impact factor: 3.240